Updated guidelines on HIV post‐exposure prophylaxis: continued efforts towards increased accessibility.

Autor: Allan‐Blitz, Lao‐Tzu^1,2 (AUTHOR) lallan-blitz@mgb.org, Mayer, Kenneth H.^2,3,4,5 (AUTHOR)

Publikováno v: Journal of the International AIDS Society. Nov2024, Vol. 27 Issue 11, p1-7. 7p.

Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005.

Autor: Toledo T; Sérgio Arouca National School of Public Health ENSP Fiocruz, Rio de Janeiro, RJ, Brazil., Oliveira VG; Evandro Chagas National Institute of Infectious Diseases INI Fiocruz, Rio de Janeiro, Brazil., Cattani VB; Evandro Chagas National Institute of Infectious Diseases INI Fiocruz, Rio de Janeiro, Brazil., Seba K; Faculty of Pharmacy, Fluminense Federal University, Rio de Janeiro, Brazil., Veloso VG; Evandro Chagas National Institute of Infectious Diseases INI Fiocruz, Rio de Janeiro, Brazil., Grinsztejn B; Evandro Chagas National Institute of Infectious Diseases INI Fiocruz, Rio de Janeiro, Brazil., Cardoso SW; Evandro Chagas National Institute of Infectious Diseases INI Fiocruz, Rio de Janeiro, Brazil., Torres TS; Evandro Chagas National Institute of Infectious Diseases INI Fiocruz, Rio de Janeiro, Brazil., Estrela R; Sérgio Arouca National School of Public Health ENSP Fiocruz, Rio de Janeiro, RJ, Brazil. rita.estrela@ini.fiocruz.br.; Evandro Chagas National Institute of Infectious Diseases INI Fiocruz, Rio de Janeiro, Brazil. rita.estrela@ini.fiocruz.br.; Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. rita.estrela@ini.fiocruz.br.

Publikováno v: Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Dec; Vol. 63 (12), pp. 1655-1666. Date of Electronic Publication: 2024 Nov 14.

Pharmacokinetics of Two Common Antiretroviral Regimens in Older HIV-Infected Patients: A Pilot Study

Autor: Prince, HMA, Kendrick, RL, Dumond, JB, Forrest, A, White, N, Wang, R, Sykes, C, Jennings, SH, Malone, S, Patterson, KB, Kashuba, ADM, Corbett, AH, Adams, JL

The pharmacokinetics (PK) of antiretrovirals (ARVs) in older HIV-infected patients are poorly described. Here, the steady-state PK of 2 common ARV regimens (tenofovir [TFV]/emtricitabine [FTC]/efavirenz [EFV]; TFV/FTC/atazanavir [ATV]/ritonavir [RTV]

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf6c8f51651c0a8b29e0c60dc4217752

Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.

Autor: Greene SA; University of North Carolina (UNC), UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; SK Life Science, Inc, Fair Lawn, New Jersey, USA., Chen J; University of North Carolina (UNC), UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Merck Co, Philadelphia, Pennsylvania, USA., Prince HMA; UNC School of Medicine, Department of Internal Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Sykes C; University of North Carolina (UNC), UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Schauer AP; University of North Carolina (UNC), UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Blake K; University of North Carolina (UNC), UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Nelson JAE; UNC School of Medicine, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Gay CL; UNC School of Medicine, Department of Internal Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Cohen MS; UNC School of Medicine, Department of Internal Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Dumond JB; University of North Carolina (UNC), UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2019 Oct; Vol. 106 (4), pp. 821-830. Date of Electronic Publication: 2019 May 31.

Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species.

Autor: Thompson CG; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Rosen EP; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Prince HMA; School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., White N; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Sykes C; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., de la Cruz G; Division of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Mathews M; Division of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Deleage C; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA., Estes JD; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA., Charlins P; Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA., Mulder LR; Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA., Kovarova M; Division of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Adamson L; Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, CA, USA., Arora S; School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Dellon ES; School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Peery AF; School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Shaheen NJ; School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Gay C; School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Muddiman DC; W.M. Keck FTMS Laboratory for Human Health Research, Department of Chemistry, North Carolina State University, Raleigh, NC, USA., Akkina R; Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA., Garcia JV; Division of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Luciw P; Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, CA, USA., Kashuba ADM; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. akashuba@unc.edu.

Publikováno v: Science translational medicine [Sci Transl Med] 2019 Jul 03; Vol. 11 (499).